SRR8518123
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.730
- INTERFERON_GAMMA_RESPONSE+0.710
- ALLOGRAFT_REJECTION+0.610
- IL6_JAK_STAT3_SIGNALING+0.580
- INFLAMMATORY_RESPONSE+0.530
- COMPLEMENT+0.510
- IL2_STAT5_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.330
- APOPTOSIS+0.290
Top 10 suppressed
- MYC_TARGETS_V2-0.380
- MYC_TARGETS_V1-0.360
- ESTROGEN_RESPONSE_EARLY-0.330
- ESTROGEN_RESPONSE_LATE-0.290
- ADIPOGENESIS-0.260
- CHOLESTEROL_HOMEOSTASIS-0.230
- NOTCH_SIGNALING-0.220
- WNT_BETA_CATENIN_SIGNALING-0.200
- UV_RESPONSE_DN-0.180
- HEDGEHOG_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-00247 | — | cohortMD2 | 0.898 |
| 2 | BSR_02_0049_A5_S69 | — | D | 0.893 |
| 3 | SRR8518387 | — | D | 0.892 |
| 4 | SRR8518332 | — | D | 0.877 |
| 5 | TCGA-75-5122-01A-01R-1755-07 | — | cohortA1 | 0.862 |
| 6 | SRR8518212 | — | D | 0.860 |
| 7 | SRR8518196 | — | D | 0.853 |
| 8 | ERR2208956 | — | — | 0.849 |
| 9 | SRR8518190 | — | D | 0.848 |
| 10 | SRR8613712 | — | D | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.730 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.710 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.610 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.530 | Idelalisib | — uncovered |
| COMPLEMENT | 0.510 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |